The Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT)
Key facts
- Who runs it
- University of Michigan
- Where
- Baltimore, Columbus, Detroit, Durham, Iowa City, Lexington, Minneapolis, Omaha, San Diego, and West Palm Beach, United StatesSee the 10 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 19 Jan 2021
- Expected to end
- 31 Aug 2027
- Type of study
- Observational
- Record updated
- 22 June 2026
Who can take part
- Age
- 16 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Enrolled in HOBIT (this is an ancillary study to the HOBIT Trial)
Who cannot take part
- Profoundly anemic (subjects who are profoundly anemic require blood transfusion)
- Blood samples cannot be obtained
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 16 and 65 years old?
This trial is currently available in United States.
Also in 1 other country, 1 site
- University of Maryland Medical CenterBaltimore, United StatesContact: Kinjal SethuramanTaking people
- OSU Wexner Medical CenterColumbus, United StatesContact: Natalie FisherNo longer taking part
- Detroit Receiving HospitalDetroit, United StatesContact: Anthony LaginaTaking people
- Duke University HospitalDurham, United StatesContact: Katherine ColtonNot yet recruiting
- University of Iowa Hospitals & ClinicsIowa City, United StatesContact: Nick MohrTaking people
- University of Kentucky HospitalLexington, United StatesContact: David DornbosTaking people
- Hennepin County Medical CenterMinneapolis, United StatesContact: Thomas BergmanTaking people
- University of Nebraska Medical CenterOmaha, United StatesContact: Natalie FisherNo longer taking part
- UCSD Medical Center - Hillcrest HospitalSan Diego, United StatesContact: Jessica WeaverTaking people
- St. Mary's Medical CenterWest Palm Beach, United StatesContact: Natalie FisherNo longer taking part
About the trial
What the trial wants to find out
There are no therapeutic agents that have been shown to improve outcomes from severe traumatic brain injury (TBI). Critical barriers to progress in developing treatments for severe TBI are the lack of: 1) monitoring biomarkers for assessing individual patient response to treatment; 2) predictive biomarkers for identifying patients likely to benefit from a promising intervention. Currently, clinical examination remains the fundamental tool for monitoring severe TBI patients and for subject selection in clinical trials. However, these patients are typically intubated and sedated, limiting the utility of clinical examinations. Validated monitoring and predictive biomarkers will allow titration of the dose of promising therapeutics to individual subject response, as well as make clinical trials more efficient by enabling the enrollment of subjects likely to benefit. Glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL) and high sensitivity c-reactive protein (hsCRP) are promising biomarkers that may be useful as 1) monitoring biomarkers; 2) predictive biomarkers in severe TBI trials. Although the biological rationale supporting their use is strong, significant knowledge gaps remain. To address these gaps in knowledge, we propose an ancillary observational study leveraging an ongoing severe TBI clinical trial that is not funded to collect biospecimen. The Hyperbaric Oxygen in Brain Injury Treatment (HOBIT) trial, a phase II randomized control clinical trial that seeks to determine the dose of hyperbaric oxygen therapy (HBOT) that that has the highest likelihood of demonstrating efficacy in a phase III trial. The proposed study will: 1) validate the accuracy of candidate monitoring biomarkers for predicting clinical outcome; 2) determine the treatment effect of different doses of HBOT on candidate monitoring biomarkers; and 3) determine whether there is a biomarker defined subset of severe TBI that responds favorably to HBOT. This proposal will: 1) inform a go/no-go decision for a phase III trial of HBOT by providing adjunctive evidence of the effect of HBOT on key biological pathways through which HBOT is hypothesized to affect outcome; 2) provide evidence to support further study of the first monitoring biomarkers of severe TBI; 3) increase the likelihood of success of a phase III trial by identifying the sub-population of severe TBI likely to benefit from HBOT; 4) create a repository of TBI biospecimen which may be accessed by other investigators.
Read full original descriptionShow less
This study is related to NCT04565119
The group in the trial
- Patients with Severe Traumatic Brain Injury
Participants will be enrolled in the HOBIT trial
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT04855396, who can take part
- Record updated
- 22 June 2026